Sputnik V authorized in Laos

Sputnik V authorized in Laos

Moscow, March 4, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health of Lao People’s Democratic Republic.

Laos has become the 44th country in the world to register Sputnik V. The vaccine was registered under the emergency use authorization procedure.

Sputnik is one of the world's top three coronavirus vaccines in terms of the number of approvals issued by government regulators. Total population of all countries where Sputnik V is approved for use to date exceeds 1.1 billion people.

Sputnik V had been approved earlier in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova, Slovakia, Angola, Republic of the Congo, Djibouti and Sri Lanka.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Registration of Sputnik V vaccine will provide an opportunity to stop the spread of coronavirus and protect the health of people in Laos. The inclusion of the Sputnik V vaccine in Laos’s national vaccine portfolio is a testament to the effectiveness of the Russian vaccine based on the well-studied platform of human adenoviral vectors. We look forward to expanding our vaccine partnership with other Asian nations.”

Sputnik V has a number of key advantages:

·        Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals; it is one of only three vaccines in the world with efficacy of over 90%; Sputnik V provides full protection against severe cases of COVID-19.

·        The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

·        Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

·        The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

·        The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.

·        There are no strong allergies caused by Sputnik V.

·        The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.

·        The price of Sputnik V is less than $10 per shot, making it affordable around the world.